Drug Profile
Pimivalimab - Concentra Biosciences
Alternative Names: JTX-4014Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Jounce Therapeutics
- Developer Concentra Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 28 Nov 2023 Jounce Therapeutics completes the phase-I/II INNATE trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, In adults, In the elderly) in USA (IV, Infusion) (NCT04669899)
- 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 01 May 2023 Jounce Therapeutics has been acquired and merged into Concentra Biosciences